Our Braizon is introduced on Nikkei Biotech article
Our platform technology was introduced in a special article on Nikkei Biotech.
Our technology is a low-invasive drug delivery technology to the brain, and our platform technology, using glucose transporter 1 of vascular endothelial cells (GLUT1), is used to deliver drugs to the brain through blood glucose control. raising delivery rate and future prospects of our technology are described
In addition, comments from our polymer scientist Shinpei Tatebayashi are also posted. Please take a look at this article because it shows the trend of DDS technology
(Sentences above were translated by Braizon Therapeutics ,Inc.)
・Article name is special feature “Drug delivery technology to the brain that is near to practical use: Issues that make it difficult to apply animal experiments results to humans in the later stages of development of drugs that reach the brain” (Oct07, 2019)
・Article URL: https://bio.nikkeibp.co.jp/atcl/report/16/082400016/100200091/
(Please note that you must register as a member to view the article.)